E. Buss

Prospective population-level validation of the Abbott ID NOW severe acute respiratory syndrome coronavirus 2 device implemented in multiple settings for testing asymptomatic and symptomatic individuals

B. Berenger, G. Tipples, W. Stokes, 2022, Clinical Microbiology and Infection.

Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern

K. Pabbaraju, T. Lynch, Matthew A. Croxen, 2022, Journal of Virological Methods.

Evaluation of the ID NOW Among Symptomatic Individuals During the Omicron Wave

B. Berenger, G. Tipples, W. Stokes, 2022, medRxiv.

Respiratory virus coinfections with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) continue to be rare one year into the coronavirus disease 2019 (COVID-19) pandemic in Alberta, Canada (June 2020–May 2021)

K. Pabbaraju, B. Berenger, J. Conly, 2021, Infection Control and Hospital Epidemiology.

Precision Response to the Rise of the SARS-CoV-2 B.1.1.7 Variant of Concern by Combining Novel PCR Assays and Genome Sequencing for Rapid Variant Detection and Surveillance

K. Pabbaraju, T. Lynch, Matthew A. Croxen, 2021, Microbiology spectrum.